Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07632157 · ClinicalTrials.gov registry record · Phase 3
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT07632157: Clinical Trial Phase 3 study, sponsored by Wake Forest University Health Sciences.
NCT07632157 is a Phase 3 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 196 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07632157, a Phase 3 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
Primary Outcome
Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of \< 120 beats per minute.
Interventions
- DRUG Saline (0.9% NaCl)
- DRUG Magnesium Sulfate 2g
- DRUG Magnesium Sulfate 4g
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2026-10 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What is known before NCT07632157 opens enrollment
NCT07632157 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which Saline (0.9% NaCl) is the first listed.
NCT07632157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07632157 about?
NCT07632157 is a clinical study titled "MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation". The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
What is the current status of trial NCT07632157?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2026-10. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07632157?
The interventions under investigation include: Saline (0.9% NaCl) (DRUG), Magnesium Sulfate 2g (DRUG), Magnesium Sulfate 4g (DRUG).
Who is sponsoring clinical trial NCT07632157?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07632157's enrollment target sits among peer trials
196 1390th of 2000 higher than 608 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia